NCT07257679

Brief Summary

This is a single-blind, parallel-group Randomized Controlled Trial (RCT) comparing the efficacy of a specialized manual technique, Gentle Touch (GT), versus a control intervention, both added to the usual rehabilitative care. The study investigates 36 women aged 30 to 75 with Breast Cancer-Related Lymphedema (BCRL). The primary objective is to evaluate the reduction of lymphedema volume in the upper limb. Secondary objectives include assessing the improvement in patients' quality of life and the potential reduction in care burden and costs. The treatment protocol involves 10 bi-weekly sessions over 5 weeks.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at below P25 for phase_4

Timeline
18mo left

Started Nov 2025

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress26%
Nov 2025Nov 2027

Study Start

First participant enrolled

November 1, 2025

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

November 17, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 2, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2027

Expected
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2027

Last Updated

December 2, 2025

Status Verified

October 1, 2025

Enrollment Period

1.2 years

First QC Date

November 17, 2025

Last Update Submit

November 27, 2025

Conditions

Keywords

LymphedemaBreast CancerDLMGentle touch

Outcome Measures

Primary Outcomes (1)

  • Change of Upper Limb Lymphedema Volume

    The volume of lymphedema will be measured volumetrically, comparing the difference in volume of the affected limb relative to the contralateral limb.

    Baseline (T0), 5 weeks (T1), and 2-month follow-up (T2)

Secondary Outcomes (4)

  • Change in Lymphedema-Specific Quality of Life (LYMQOL)

    Baseline (T0), 5 weeks (T1), and 2-month follow-up (T2)

  • Change in Upper Limb Function and Disability (DASH)

    Baseline (T0), 5 weeks (T1), and 2-month follow-up (T2)

  • Change in General Health (SF-36)

    Baseline (T0), 5 weeks (T1), and 2-month follow-up (T2)

  • Change in Well-being (PROMIS-29)

    Baseline (T0), 5 weeks (T1), and 2-month follow-up (T2)

Study Arms (2)

Gentle Touch (GT) Lymphatic Drainage + Usual Care

EXPERIMENTAL

Participants in this arm will receive the Gentle Touch (GT) lymphatic drainage technique, which is based on the ANDOS manual technique, in addition to their existing rehabilitation pathway. The GT is a tactile stimulus applied to the skin aimed at promoting relaxation, improving pain, sleep management, and therapeutic participation. The treatment involves 10 sessions administered with a bi-weekly frequency.

Other: Gentle Touch (GT) Lymphatic Drainage (ANDOS technique)

Passive Mobilization and Active-Assisted Exercises + Usual Care

ACTIVE COMPARATOR

Participants in this arm will receive 10 sessions of passive mobilization and active-assisted exercises for the upper limb. This is provided in addition to the existing rehabilitation program. The sessions will be carried out with the same frequency (bi-weekly) as the experimental group.

Other: Passive Mobilization and Active-Assisted Exercises for the Upper Limb

Interventions

This intervention involves the application of a specific tactile stimulus (Gentle Touch) to the skin. This stimulus is designed to promote relaxation, alleviate social isolation and stress, and provide emotional support. The goal is to stimulate fluid movement in the skin, increasing lymphatic flow, attenuating fibrosis, and reducing pain. This approach (GT-based ANDOS technique) is added to the participant's existing rehabilitation program. The intervention is administered by a specifically trained physiotherapist. Dosage: 10 sessions. Frequency: Bi-weekly.

Gentle Touch (GT) Lymphatic Drainage + Usual Care

This intervention consists of passive mobilization and active-assisted exercises for the affected upper limb. This intervention is given in addition to the participant's existing rehabilitation program. This is the control intervention to which the experimental GT approach is compared. It is administered by a specifically trained physiotherapist. Dosage: 10 sessions. Frequency: Bi-weekly (same as the experimental group).

Passive Mobilization and Active-Assisted Exercises + Usual Care

Eligibility Criteria

Age30 Years - 75 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Gender: Women.
  • Age: Between 30 and 75 years old
  • Surgical History: Women who have undergone surgery for breast cancer (BC). This includes being subjected to one of the following interventions: Axillary dissection with removal of all 3 lymph node levels; Axillary dissection with removal of only one lymph node level; Removal of the sentinel lymph node only.
  • Clinical Lymphedema: Clinically evaluated lymphedema symptoms, defined as a circumference difference of greater than 20mm between the two arms

You may not qualify if:

  • Concurrent Diseases: Concomitant diseases that may interfere with the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Santa Lucia Foundation IRCCS

Roma, RM, 00179, Italy

ACTIVE NOT RECRUITING

Santa Lucia Foundation, Scientific Institute for Research and Health Care

Roma, RM, 00179, Italy

RECRUITING

Related Publications (4)

  • Loibl S, Andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. No abstract available.

    PMID: 38101773BACKGROUND
  • Fu MR, Ridner SH, Hu SH, Stewart BR, Cormier JN, Armer JM. Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncology. 2013 Jul;22(7):1466-84. doi: 10.1002/pon.3201. Epub 2012 Oct 9.

    PMID: 23044512BACKGROUND
  • Thompson B, Gaitatzis K, Janse de Jonge X, Blackwell R, Koelmeyer LA. Manual lymphatic drainage treatment for lymphedema: a systematic review of the literature. J Cancer Surviv. 2021 Apr;15(2):244-258. doi: 10.1007/s11764-020-00928-1. Epub 2020 Aug 15.

    PMID: 32803533BACKGROUND
  • Sezer Efe Y, Erdem E, Caner N, Gunes T. The effect of gentle human touch on pain, comfort and physiological parameters in preterm infants during heel lancing. Complement Ther Clin Pract. 2022 Aug;48:101622. doi: 10.1016/j.ctcp.2022.101622. Epub 2022 Jun 22.

    PMID: 35759976BACKGROUND

MeSH Terms

Conditions

Breast Cancer LymphedemaLymphedemaBreast Neoplasms

Condition Hierarchy (Ancestors)

Lymphatic DiseasesHemic and Lymphatic DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Diego Piatti, PT

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 17, 2025

First Posted

December 2, 2025

Study Start

November 1, 2025

Primary Completion (Estimated)

January 15, 2027

Study Completion (Estimated)

November 1, 2027

Last Updated

December 2, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations